

# Focus of research group (I)

Name PI: Michiel Coppens

Department, UMC: Vascular Medicine/Hemophilia  
Treatment Centre

Size of research group:

PhD candidates: Bavalia, Hamulyak (thrombosis),  
Zwagemaker, Kloosterman, Abdi (bleeding)

## Current mission, vision and aims

1. Clinical research that can directly impact patient care.
  - a) Management and outcome of anticoagulant associated bleeding
  - b) Management of menorrhagia in women treated with oral anticoagulation.
  - c) Oral resorption of DOACs in patients with short bowel syndrome
  - d) Gene therapy for haemophilia A/B
  - e) Bleeding phenotype in non-severe haemophilia



Heart Failure & Arrhythmias



Pulmonary Hypertension  
& Thrombosis



Atherosclerosis  
& Ischemic Syndromes



Diabetes & Metabolism



Microcirculation

# Focus of research group (II)



Heart Failure & Arrhythmias



Pulmonary Hypertension  
& Thrombosis



Atherosclerosis  
& Ischemic Syndromes



Diabetes & Metabolism



Microcirculation

## Current expertise

1. Reversal of DOACs / Bleeding registr(ies)
2. Menorrhagia (collaboration Middeldorp)
3. Oral DOAC resorption in Short Bowel Syndrome (collaboration Mathot/Serlie)
  - Successful pilot, prospective cohort ongoing
4. Gene therapy
  - Steering committee AMT-060/Uniquire Phase I/II
5. Phenotype in non-severe haem A/B (collaboration Fijnvandraat)
  - Dynamo, Flow cohorts
6. National haemophilia collaborations
  - HiN-6, TiN, Opticlot, DAVID, Pride

## Current funding

- ZonMW GGG (in afronding)
- CSL Behring Heimburger Grant
- Bayer Haemophilia Awards Program
- Vierde geldstroom



Heart Failure & Arrhythmias



Pulmonary Hypertension  
& Thrombosis



Atherosclerosis  
& Ischemic Syndromes



Diabetes & Metabolism



Microcirculation

# Future plans

## Short term (1-2 year) plan

### Plan:

- Wrap-up ZonMW GGG Grant. Explore international continuation of cohort
- Successful rollout of prospective TPN cohort (expansion to Radboud)
  - Expand to bariatric surgery patients?
- Gene therapy haemophilia
  - PI phase 3 AMT-061/UniQure
  - PI phase I Bayer
- Active participation in current national collaborations

### Necessary infrastructure:

- HPLC DOACs (through Mathot)
- Affordable GCP-quality monitoring/support of IIS

## Long term (>2 year) plan

### Plan:

Try and remain active in two different fields...

## Collaboration in ACS

Middeldorp